In a small Finnish study of 29 healthy adults, a blood pressure pill paired with a vibrating mattress session appeared to nudge Alzheimer's-linked proteins into the bloodstream, a result that echoes how the brain naturally clears its waste during sleep. It is a modest step in a long human effort to understand how the mind quietly accumulates damage over decades, and whether that process can be interrupted before memory begins to fade. The researchers themselves are careful: the findings describe what happened in blood, not in the brain, and not in anyone's memory. What they offer is a hypothes
Vibrating Mattress and Blood Pressure Pill Shift Alzheimer's-Linked Proteins in Small Trial
A mattress built to mimic the brain's nighttime cleanup
Mark
So what actually happened in this trial?
Mimi
Twenty-nine healthy adults took a blood pressure pill, twice, then lay on a vibrating mattress for just over half an hour. Afterward, amyloid beta and GFAP were higher in their blood.
Mark
Why would higher blood levels be good news?
Mimi
The researchers read it as proteins being flushed out of the brain. The mattress is meant to imitate the slow pulses of the brain's nighttime clearance.
Luke
But that's an interpretation. Nobody measured protein in the brain itself.
Mimi
Right, and the team says so. They also note the rise could partly reflect a temporarily looser blood-brain barrier.
Luke
And tau, the protein most tied to Alzheimer's progression, didn't move.
Mimi
That's a real limit on what this shows.
Mark
Anything that supports their reading?
Mimi
The effect was bigger in older people and in those whose blood pressure fell more. The scans also showed clearance in veins at the back of the brain, which matches lying on your back.
Luke
Still, no memory or cognition results were reported, and everyone was healthy. Whether this helps anyone with dementia is unknown.
Mark
So what's next?
Mimi
Longer studies, and people with early memory impairment, which the team is planning now.
Der Puls
- A 29-person trial in Finland found that a blood pressure pill plus a vibrating mattress session raised blood levels of amyloid beta and GFAP, two proteins tied to Alzheimer's.
- The idea borrows from sleep, when the brain's waste-removal system surges and slow pulses help sweep out material that should not linger.
- Researchers cannot yet tell whether the rise means proteins were cleared from the brain or whether the blood-brain barrier was simply loosened.
- Tau levels stayed unchanged, and no memory or cognitive tests were run, so the study cannot confirm any benefit.
- The team is now planning longer studies in people with early memory impairment to see whether the approach offers real clinical help.
In a small Finnish study of 29 healthy adults, a blood pressure pill paired with a vibrating mattress session appeared to nudge Alzheimer's-linked proteins into the bloodstream, a result that echoes how the brain naturally clears its waste during sleep. It is a modest step in a long human effort to understand how the mind quietly accumulates damage over decades, and whether that process can be interrupted before memory begins to fade. The researchers themselves are careful: the findings describe what happened in blood, not in the brain, and not in anyone's memory. What they offer is a hypothesis worth testing, not a remedy yet within reach.
Twenty-nine healthy adults, aged 27 to 61, took part in a study in Finland that looks more like a sleep-clinic experiment than an Alzheimer's trial. Each took two doses of a blood pressure-lowering pill, then lay on a vibrating mattress for a little over half an hour. Afterward, blood tests showed higher levels of proteins linked to Alzheimer's disease.
The method is inspired by sleep. At night, the brain's waste-removal system becomes active, as blood pressure in the brain drops and slow pulses help clear away material that should not remain. The team at the University of Oulu designed the mattress vibrations to mimic those pulses, and the pill to reproduce the pressure drop. Their findings, published in Nature Communications, showed rising levels of two forms of amyloid beta and of GFAP, a protein that supports brain cells called astrocytes. Tau, the protein most closely tied to disease progression, did not change.
The researchers saw signs that fit their hypothesis. Older participants and those whose blood pressure fell further showed larger effects, and brain scans pointed to clearance in veins at the back of the brain. Still, the limits are real. The volunteers had no dementia, brain proteins were measured only in blood, no memory tests were conducted, and higher blood levels could reflect a temporarily leakier blood-brain barrier. The test was also a single session.
Neuroradiologist Vesa Kiviniemi framed the stakes simply: harmful proteins build up over decades, and the brain's clearance weakens with age. If that system can be safely strengthened early, prevention or slowing might one day be possible. For now, the next step is to learn whether the approach can help people already experiencing early memory problems, with follow-up studies being planned.
Twenty-nine healthy adults, aged 27 to 61, took part in a trial in Finland that sounds more like a sleep-clinic experiment than an Alzheimer's study. Each received two doses of a blood pressure-lowering pill, then lay on a vibrating mattress for a little over half an hour. Afterward, blood tests showed higher levels of certain proteins linked to Alzheimer's disease.
The idea behind the setup is borrowed from sleep. The brain has a waste-removal system that works mainly at night. Blood pressure in the brain drops, and slow pulses help sweep out material that shouldn't linger, readying the brain for morning. The Oulu team's mattress vibrations were designed to mimic those pulses, and the pill was meant to reproduce the pressure drop.
The team, led by researchers at the University of Oulu, reported its findings in Nature Communications. Two forms of amyloid beta, which clumps together in Alzheimer's disease, rose in the blood. So did glial fibrillary acidic protein, or GFAP, which supports brain cells called astrocytes. The researchers read that rise as a sign the proteins had been cleared out of the brain. Tau, the protein most closely tied to Alzheimer's progression in the brain, did not change.
Some details fit the researchers' hypothesis. The effect was larger in older participants and in those whose blood pressure dropped further. Brain scans showed the clearance occurring in veins at the back of the brain, which is where gravity would be expected to direct it in people lying on their backs. Biomedical engineer Johanna Tuunanen said the effect largely resembled physiological changes the group had previously observed during sleep, and that the results suggest harmful proteins were cleared more efficiently than usual.
Neuroradiologist Vesa Kiviniemi framed the stakes in terms of time. Alzheimer's and other dementias, he said, involve harmful proteins accumulating over decades, and the brain's clearance system grows less effective with age. If it can be safely boosted while people are still healthy, he said, it may eventually be possible to prevent these diseases or slow them.
The limitations are substantial. The volunteers were healthy and had no dementia. Protein levels in the brain were not measured directly, only in the blood. The study reported no memory or other cognitive test results. The researchers also acknowledge that higher blood levels could mean the treatment temporarily loosened the blood-brain barrier, rather than, or in addition to, actively pushing proteins out of the brain.
Even so, the work builds on earlier experiments in mouse models, and it offers a first look at the approach in people. The test was a single session, so nothing is known about repeated use over time.
Kiviniemi said the next step is to examine what benefit the treatment might offer patients with early-stage memory impairment, and that follow-up studies are being planned with other experts in the field.
Bemerkenswerte Zitate
The results suggest that harmful proteins were cleared from the brain more efficiently than usual.— Johanna Tuunanen, biomedical engineer, University of Oulu
The next step is to investigate what benefits the treatment might offer patients with early-stage memory impairment.— Vesa Kiviniemi, neuroradiologist, University of Oulu
Möchten Sie die ganze Geschichte?
Das Original lesen bei ScienceAlert ↗
Health & Medicine